Navigation Links
Apelin to rescue diabetics
Date:11/4/2008

Sugar is naturally present in the blood in the form of glucose and is stored in the liver or adipose tissue (fat) thanks to the action of insulin. Glucose is stored or directly used to ensure satisfactory function of the heart, brain and so on according to the body's demands.

In certain cases, this mechanism may deteriorate either because insulin is no longer produced (type 1 diabetes), or because the receptors located on the surface of liver cells are desensitized (type II diabetes). Consequently, the cell is no longer capable of assimilating glucose. Such a dysfunction causes a rise in blood sugar levels leading to the onset of numerous complications.

Philippe Valet's team has just found that our cells are equipped with a second pathway for the assimilation of glucose. This discovery is based on a protein called "apelin".1

This protein is not only a "key" that is different from insulin; it also passes through a different receptor or "doorway".

In type II diabetics where the receptor or doorway is impaired rather than the key, this discovery makes it possible to envisage effective treatment. The results observed by Philippe Valet's team make it possible to short-circuit this mechanism and achieve sugar assimilation by a completely different pathway from that mediated by insulin.

Normally, this second pathway is only responsible for a small proportion of sugar integration. However, as proved by tests conducted in mice by Inserm researchers, in the case of type II diabetes, activation of this second route improves the regulation of blood sugar levels. "We now have to check the action of this protein in man. In parallel, we are developing a synthetic molecule that may be used if the tests in man are positive," concluded Philippe Valet.


'/>"/>

Contact: Severine Ciancia
presse@inserm.fr
33-144-236-097
INSERM (Institut national de la sant et de la recherche mdicale)
Source:Eurekalert

Page: 1

Related biology news :

1. Can you rescue a rainforest? The answer may be yes
2. Rabbits to the rescue of the reef
3. Survey finds elevated rates of new asthma among WTC rescue and recovery workers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... Brooklyn, NY (PRWEB) , ... June 24, 2016 , ... ... 15mm, machines such as the Cary 5000 and the 6000i models are higher end ... height is the height of the spectrophotometer’s light beam from the bottom of the ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology: